Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Juli 2018

Planlagt Fastgjort Låst Flyttet Genmab
1.3k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • SolsenS Offline
    SolsenS Offline
    Solsen
    wrote on sidst redigeret af
    #947

    The mechanism of immune resistance to anti-PD- L1/PD-1 therapy caused by CD38 provides an evident rationale for recruitment of cancer patients for clinical trials of anti-CD38 in combination with anti-PD-L1/PD-1 to prevent therapy resistance and further enhance anti-tumor efficacy.

    1 Reply Last reply
    0
    • SolsenS Offline
      SolsenS Offline
      Solsen
      wrote on sidst redigeret af
      #948

      It looks like a new article to me.

      1 Reply Last reply
      0
      • G Offline
        G Offline
        gentogen
        wrote on sidst redigeret af
        #949

        Der er fire forskellige:

        1 Reply Last reply
        0
        • G Offline
          G Offline
          gentogen
          wrote on sidst redigeret af
          #950

          CD38 as a novel immune checkpoint and a mechanism of resistance to the blockade of the PD-1/PD-L1 axis.
          L Chen, LA Byers, S Ullrich, II Wistuba, XF Qin… - 2017 - ascopubs.org

          1 Reply Last reply
          0
          • G Offline
            G Offline
            gentogen
            wrote on sidst redigeret af
            #951

            Targeting CD38 to improve anti-PD-1/CTLA-4 combination therapy in lung cancer.
            L Chen, Y Li, X Yi, DL Gibbons - 2018 - ascopubs.org

            1 Reply Last reply
            0
            • G Offline
              G Offline
              gentogen
              wrote on sidst redigeret af
              #952

              CD38 blockade overcomes the immune resistance to anti-PD-L1 therapy by boosting CD8 T cell response
              L Chen, L Diao, Y Yang, X Yi, J Rodriguez, Y Fan… - 2017 - AACR

              1 Reply Last reply
              0
              • G Offline
                G Offline
                gentogen
                wrote on sidst redigeret af
                #953

                CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade
                L Chen, L Diao, Y Yang, X Yi, BL Rodriguez, Y Li… - Cancer Discovery, 2018 - AACR

                1 Reply Last reply
                0
                • G Offline
                  G Offline
                  gentogen
                  wrote on sidst redigeret af
                  #954

                  Fra nummer to: Conclusions: Targeting CD38 improves the efficacy of anti-PD-1/CTLA-4 combination therapy in lung cancer. CD38 on tumor cells could potentially serve as a novel biomarker of resistance for immune checkpoint inhibition."

                  1 Reply Last reply
                  0
                  • G Offline
                    G Offline
                    gentogen
                    wrote on sidst redigeret af
                    #955

                    tumor bearing mice treated with combined PD-1 and CTLA-4 blocking antibodies developed resistance through the up-regulation of CD38, and that targeting CD38 abolished the resistance in a manner dependent on B7-costimulation

                    1 Reply Last reply
                    0
                    • Legolas23L Offline
                      Legolas23L Offline
                      Legolas23
                      wrote on sidst redigeret af
                      #956

                      Bliver spændende om BMS-studierne kommer op med resultater, som underbygger.

                      1 Reply Last reply
                      0
                      • Legolas23L Offline
                        Legolas23L Offline
                        Legolas23
                        wrote on sidst redigeret af
                        #957

                        Hvad tænker du?

                        1 Reply Last reply
                        0
                        • G Offline
                          G Offline
                          gentogen
                          wrote on sidst redigeret af
                          #958

                          Fra nummer fire hedder det: "Overall the therapeutic studies demonstrate that combination CD38 and PD-L1 blockade substantially reduces primary tumor burden and
                          metastases, that CD38 can be used in combination or in a sequential manner upon the
                          acquisition of resistance, and that targeting CD38 or the downstream adenosine
                          signaling is highly effective.

                          1 Reply Last reply
                          0
                          • G Offline
                            G Offline
                            gentogen
                            wrote on sidst redigeret af
                            #959

                            To model how CD38-blocking strategies might be translated into the clinic for patients
                            with disease refractory to anti-PD-1/PD-L1, we tested sequential treatment after the
                            development of resistance to anti-PD-L1 by treating animals with anti-CD38 antibody
                            alone.

                            1 Reply Last reply
                            0
                            • G Offline
                              G Offline
                              gentogen
                              wrote on sidst redigeret af
                              #960

                              We observed a substantial inhibition of tumor growth with an associated
                              enhancement of the effector CD8+
                              and CD4+
                              T cell responses and blunting of the
                              suppressor CD4+
                              T regulatory and MDSC populations, highlighting that CD38 is an
                              independent factor in treatment-induced resistance

                              1 Reply Last reply
                              0
                              • G Offline
                                G Offline
                                gentogen
                                wrote on sidst redigeret af
                                #961

                                Kildeangivelse: Downloaded from cancerdiscovery.aacrjournals.org on July 21, 2018. © 2018 American Association for Cancer Research

                                1 Reply Last reply
                                0
                                • G Offline
                                  G Offline
                                  gentogen
                                  wrote on sidst redigeret af
                                  #962

                                  jf tidligere link

                                  1 Reply Last reply
                                  0
                                  • G Offline
                                    G Offline
                                    gentogen
                                    wrote on sidst redigeret af
                                    #963

                                    Jeg er ikke ekspert nok til at tænke så meget, men det lyder meget overbevisende....så jeg bliver bestemt ikke overrasket, hvis studier fortsætter

                                    1 Reply Last reply
                                    0
                                    • BulderB Offline
                                      BulderB Offline
                                      Bulder
                                      wrote on sidst redigeret af
                                      #964

                                      Men det forklarer stadig ikke hvorfor kontrolgruppen i dara-atezo s
                                      tudiet klarede sig lige så godt som eksp. gruppen

                                      1 Reply Last reply
                                      0
                                      • BulderB Offline
                                        BulderB Offline
                                        Bulder
                                        wrote on sidst redigeret af
                                        #965

                                        ... og hvori safety problemet bestod.

                                        1 Reply Last reply
                                        0
                                        • M Offline
                                          M Offline
                                          Mcjean
                                          wrote on sidst redigeret af
                                          #966

                                          Hvem siger der var et safety problem Bulder? 😉

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger